Companies › Guangdong Raynovent Biotech
3 active drug programs in 7 registered trials: 3 Phase 3, 3 Phase 2, 1 Phase 1; Infectious disease, Metabolic and endocrine, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RAY1225 Unclear - mechanism not specified in registry text | – | Phase 3 | Obesity; T2DM (Type 2 Diabetes Mellitus) | – |
| ZSP1273 Neuraminidase inhibitor | – | Phase 3 | Influenza A; Influenza a | – |
| ZSP1601 FGF21 receptor agonist | – | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06254274 | RAY1225 | Phase 2 | T2DM (Type 2 Diabetes Mellitus) | Metabolic and endocrine | Jul 2025 |
| NCT06254261 | RAY1225 | Phase 2 | Obesity | Metabolic and endocrine | Dec 2025 |
| NCT07229820 | ZSP1273 | Phase 3 | Influenza A | Infectious disease | Dec 2025 |
| NCT07362030 | RAY1225 | Phase 1 | Obesity | Metabolic and endocrine | Dec 2025 |
| NCT07229807 | ZSP1273 | Phase 3 | Influenza a | Infectious disease | Jan 2026 |
| NCT06893016 | RAY1225 | Phase 3 | Obesity | Metabolic and endocrine | Jun 2026 |
| NCT05692492 | ZSP1601 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | Gastroenterology | Dec 2026 |
No annotated target.
–
Madrigal Pharmaceuticals Rivus Pharmaceuticals Insud Pharma Visirna Therapeutics HK Eccogene
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.